Human secretin is a gastrointestinal peptide hormone that regulates secretions in the stomach, pancreas, and liver. Synthetic human secretin displays equivalent biological activity and properties as naturally occurring secretin. Acetate salt of synthetic secretin was marketed under the name ChiRhoStim. ChiRhoStim is indicated for the stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, for the gastrin secretion to aid in the diagnosis of gastrinoma. ChiRhoStim is also used for the pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic, retrograde cholangiopancreatography (ERCP). When secretin binds to secretin receptors on pancreatic duct cells it opens cystic fibrosis transmembrane conductance regulator (CFTR) channels, leading to secretion of bicarbonate-rich-pancreatic fluid.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P47872 Gene ID: 6344.0 Gene Symbol: SCTR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21542831 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | ChiRhoStim Approved UseChiRhoStim® is a secretin class hormone indicated for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction; gastrin secretion to aid in the diagnosis of gastrinoma; pancreatic secretions to facilitate the identification of the ampulla of Vater and the accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). Launch Date2004 |
Sample Use Guides
Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction: 0.2 mcg/kg by intravenous injection over 1 minute
Stimulation of gastrin secretion to aid in diagnosis of gastrinoma:0.4 mcg/kg by intravenous injection over 1 minute
Stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography ERCP): 0.2 mcg/kg by intravenous injection over 1 minute
Route of Administration:
Intravenous
| Substance Class |
Protein
Created
by
admin
on
Edited
Mon Mar 31 21:40:34 GMT 2025
by
admin
on
Mon Mar 31 21:40:34 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
RK90J5778U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
914454-02-7
Created by
admin on Mon Mar 31 21:40:34 GMT 2025 , Edited by admin on Mon Mar 31 21:40:34 GMT 2025
|
PRIMARY | |||
|
118984464
Created by
admin on Mon Mar 31 21:40:34 GMT 2025 , Edited by admin on Mon Mar 31 21:40:34 GMT 2025
|
PRIMARY | |||
|
RK90J5778U
Created by
admin on Mon Mar 31 21:40:34 GMT 2025 , Edited by admin on Mon Mar 31 21:40:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
STARTING MATERIAL -> INGREDIENT | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Agent Modifications
| Modification Process | Modification Role | Modification Type | Amount | Fragment Name | Fragment ID |
|---|---|---|---|---|---|
| ACETYLATION | CHEMICAL | Acetic acid | Q40Q9N063P |
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO ACID SUBSTITUTION | [1_27] | V | VALINAMIDE | JCM10841JE |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|